{
  "model": "gpt-oss-120b",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gpt-oss-120b-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 167912,
  "agentCostUsd": 0,
  "graderCostUsd": 0.01553475,
  "totalCostUsd": 0.01553475,
  "agentUsage": {
    "promptTokens": 68291,
    "cachedTokens": 6447,
    "responseTokens": 9500,
    "thinkingTokens": 0,
    "totalTokens": 77791
  },
  "graderUsage": {
    "promptTokens": 3861,
    "cachedTokens": 0,
    "responseTokens": 373,
    "thinkingTokens": 254,
    "totalTokens": 4488
  },
  "totalUsage": {
    "promptTokens": 72152,
    "cachedTokens": 6447,
    "responseTokens": 9873,
    "thinkingTokens": 254,
    "totalTokens": 82279
  },
  "modelVersions": [
    "accounts/fireworks/models/gpt-oss-120b"
  ],
  "agentFinalText": "Checklist of written output files:\n- output/study_overview.json\n- output/quantitative_findings.json\n- output/claim_audit.json\n- output/public_summary.json\n\nAll required JSON outputs have been created.",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade and improve therapeutic outcomes?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"c1\",\n      \"label\": \"mouse efficacy\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Combination of intratumoral mRNA vaccine and anti‑PD‑L1 treatment across multiple murine tumor models (L19-L20).\"\n    },\n    {\n      \"id\": \"c2\",\n      \"label\": \"mouse control\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Matched control groups receiving vaccine only, ICI only, or vehicle (L19-L20).\"\n    },\n    {\n      \"id\": \"c3\",\n      \"label\": \"human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic cancer patients treated with ICIs, stratified by prior SARS‑CoV‑2 mRNA vaccination status (L21-L23).\"\n    },\n    {\n      \"id\": \"c4\",\n      \"label\": \"human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort who received an mRNA vaccine before ICI (L22-L23).\"\n    },\n    {\n      \"id\": \"c5\",\n      \"label\": \"human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective cohort without prior mRNA vaccination (L22-L23).\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non‑randomized, introducing potential confounding (L48-L51).\",\n    \"Vaccination timing relative to ICI initiation varied among patients (L50-L51).\",\n    \"Mouse model findings may not translate directly to diverse human tumor types (L52-L53).\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L35\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling, initiating downstream antitumor immunity.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"2. Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Evidence is based on preclinical murine models and may not fully translate to humans.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination broadens the tumor immunopeptidome, increasing the fraction of tumor proteins presented on MHC molecules.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"The magnitude of expansion is measured in murine tumors and may differ in human cancers.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD‑L1 expression in tumor tissue increases after mRNA vaccination, enhancing the targetability of checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"PD‑L1 up‑regulation may reflect an adaptive resistance mechanism rather than a purely beneficial effect.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combining intratumoral mRNA vaccination with anti‑PD‑L1 therapy improves tumor control in mice and is associated with improved survival in a retrospective human cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Human evidence is retrospective, non‑randomized, and subject to confounding factors.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"Intratumoral mRNA vaccines boost checkpoint inhibitor effectiveness but need human trials\",\n  \"plain_language_summary\": \"The researchers tested whether delivering an mRNA vaccine directly into mouse tumors could make the tumours more visible to the immune system and therefore respond better to drugs that block the PD‑L1 checkpoint. In several mouse models the vaccine increased interferon signals, broadened the range of tumour proteins presented on MHC‑I molecules and raised PD‑L1 levels, leading to stronger tumour control when combined with anti‑PD‑L1 therapy. A retrospective analysis of 130 metastatic cancer patients showed that those who had received a SARS‑CoV‑2 mRNA vaccine before starting checkpoint blockade survived longer (p=0.01). However, the human data are observational, the timing of vaccination varied, and mouse results may not translate to all human cancers. The study suggests a promising biological strategy but calls for prospective, randomised trials before clinical recommendations.\",\n  \"what_is_new\": [\n    \"mRNA vaccination directly inside tumours expands the immunopeptidome, exposing more tumour antigens to immune cells.\",\n    \"Type I interferon response scores rise sharply after intratumoral mRNA vaccination, indicating potent innate activation.\",\n    \"Retrospective human patients with prior SARS‑CoV‑2 mRNA vaccination showed improved survival under checkpoint blockade (p=0.01).\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival benefit comes from a non‑randomised, retrospective cohort, which may be confounded by other factors.\",\n    \"Vaccination timing relative to immunotherapy varied among patients, making causal inference uncertain.\",\n    \"Mouse tumour models do not capture the full diversity of human cancers, so results may not be generalisable.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A therapeutic that delivers messenger RNA encoding antigens, prompting cells to produce the antigen and stimulate an immune response.\"\n    },\n    {\n      \"term\": \"checkpoint inhibitor\",\n      \"definition\": \"A drug that blocks proteins such as PD‑L1, releasing the brakes on T‑cells to allow them to attack cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"immunopeptidome\",\n      \"definition\": \"The complete set of peptide fragments displayed on a cell's MHC molecules, representing the antigens presented to T‑cells.\"\n    },\n    {\n      \"term\": \"type I interferon\",\n      \"definition\": \"A family of cytokines (e.g., IFN‑α, IFN‑β) produced during viral sensing that enhance antigen presentation and immune activation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will intratumoral mRNA vaccination improve outcomes in prospective randomised human trials?\",\n    \"What is the optimal timing and dosing schedule for combining mRNA vaccines with checkpoint inhibitors?\",\n    \"Can this strategy be effective across diverse tumour types beyond the preclinical models tested?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 26,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 13,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-16T12:52:57.567Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-16T12:52:59.021Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-16T12:53:00.576Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-16T12:53:02.676Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-16T12:53:04.026Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-16T12:53:05.847Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-16T12:53:07.384Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-16T12:53:44.019Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-16T12:54:10.602Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-16T12:54:29.528Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-16T12:54:48.647Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-16T12:55:12.637Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-16T12:55:28.543Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 4,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [
        "Invalid line reference: In output/quantitative_findings.json, the control statement \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\" cites evidence_line_ref \"L35\", but L35 is only the section header \"## Controls and Null/Conditional Results\". The actual supporting line is L36. This breaks the requirement that line references are valid and map to the numbered report lines.",
        "Incomplete coverage of key controls/null results: The outputs omit (i) ICI-only had limited activity in low-immunogenic settings (L37) and (ii) lipid particle controls lacking mRNA did not reproduce the sensitization effect (L38). These are core negative/control findings that help establish the mechanistic specificity.",
        "Incomplete coverage of caveats: The limitations list in output/study_overview.json misses important human-cohort caveats explicitly stated in the report, including tumor-type mix/treatment-history heterogeneity limiting causal interpretation (L51) and that some mechanistic readouts were strongest in specific model systems rather than uniform (L53)."
      ],
      "summary": "Most quantitative values and major mechanistic claims are consistent with the report and do not introduce new numbers. However, at least one cited line reference is incorrect (a strict failure under the rubric), and the outputs omit multiple key control results (L37–L38) and several explicitly stated limitations (L51, L53). These issues reduce downstream auditability and practical usefulness for review, so the set should not pass as-is."
    }
  }
}
